Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE BESYLATE VALSARTAN AND HYDROCHLOROTHIAZIDE versus FILSPARI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE BESYLATE VALSARTAN AND HYDROCHLOROTHIAZIDE versus FILSPARI.
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE vs FILSPARI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, causing vasodilation and reduced peripheral resistance. Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone release. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, increasing sodium and water excretion.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
One tablet orally once daily. Available strengths: amlodipine 5 mg/valsartan 160 mg/HCTZ 12.5 mg, amlodipine 5 mg/valsartan 160 mg/HCTZ 25 mg, amlodipine 10 mg/valsartan 160 mg/HCTZ 12.5 mg, amlodipine 10 mg/valsartan 160 mg/HCTZ 25 mg, amlodipine 10 mg/valsartan 320 mg/HCTZ 25 mg. Titrate based on response, max dose: amlodipine 10 mg/valsartan 320 mg/HCTZ 25 mg daily.
200 mg orally once daily, with or without food.
None Documented
None Documented
Amlodipine: 30-50 hours (terminal, allows once-daily dosing); Valsartan: 6 hours; Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Amlodipine: 60% renal, 20-25% biliary/fecal; Valsartan: 83% fecal via bile, 13% renal; Hydrochlorothiazide: ≥95% renal as unchanged drug.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Category D/X
Category C
ARB
Endothelin Receptor Antagonist / ARB